Hyzaar Asia HEAALTH (0954A-950)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 3

Conditions: Hypertension

Treatments: Drug: losartan potassium (+) hydrochlorothiazide

Study type: Interventional

Funder types: Industry

Identifiers

NCT00354991

MK0954A-950

0954A-950

2006_012

Details and patient eligibility

About

The objective of the study is to estimate the percentage of patients who reach blood pressure goal after 8 weeks of treatment with losartan/HCTZ combination.

Enrollment: 437 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient is male or female and = 18 years of age
• Patients with essential hypertension previously treated with antihypertensive medications for at least 4 weeks but did not reach the blood pressure goal

Exclusion criteria

• History of any condition, therapy, lab abnormality or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study, such that it is not in the best interest of the patient/subject to participate
• Pregnant or breastfeeding, or expecting to conceive within the projected duration of the study
• Previous history of severe essential hypertension
• History of stroke or myocardial infarction (heart attack)
• Evidence of renal or liver disease
• Uncontrolled diabetes mellitus
• Any known bleeding disorder
• Known sensitivity or intolerance to the study medication (losartan or hydrochlorothiazide)
• Other antihypertensive medications or medications that may affect blood pressure

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

437 participants in 1 patient group

1

Experimental group

Description:

Losartan/HCTZ

Treatment:

Drug: losartan potassium (+) hydrochlorothiazide